About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
Biocon Quarterly Results
  > INVESTORS
  Overview
  Corporate Structure
  Corporate Governance
  Company History
  Annual General Meeting
  Investor FAQs
  Stock Info
  Financial Results
  Subsidiary Financials
  Annual Report
  Disclosure to Stock Exchange
  Press Releases
  Presentations
  Analyst Coverage
  Investor Contacts
  
  Home
  
     
 
Financials

Financial Results

 
 
  Consolidated Financial Performance (FY11-15)

All Figures in Rs. Crores except EPS 

Business Segment FY15 FY14 FY13 FY12 FY11
 Biopharmaceuticals

2236

2138 1871 1676 1487
   - Biopharma 1807 1747 1523 1417 1302
   - Branded
     Formulations
430 391 347 259 186
 Contract Research 823 715 557 410 318
 Total Sales 3059 2853 2423 2087 1806
 Other Income 84 80 110 62 52
 Total Revenue 3143 2933 2538 2148 1858
 EBITDA 749 743 596 579 573
 EBITDA Margin (%) 24% 25% 23% 27% 31%
 Net Profit* 402 414 324 338 340
 Net Profit Margin 13% 14% 13% 16% 18%
 EPS 24.8 20.7 25.4 16.9 18.4
 R&D Spends
 (in P&L)
169 131 164 157 118
 R&D (as % of
 Biopharmaceuticals
 Sales)
7.5% 6.1% 8.8% 9.3% 7.9%

 *Net Profit is pre-exceptional


Current Financial Year 2015-16

  FY 15-16 Q1 H1 9M FY
  Notice Ad - - Press Release Q2 FY 2015-16 Press Release Q2 FY 2015-16
  Press Release Press Release Q1 FY 2015-16 Press Release Q2 FY 2015-16 Press Release Q3 FY 2015-16 Press Release Q4 FY 2015-16
  Fact Sheet Fact Sheet Q1 FY 2015-16 Fact Sheet Q2 FY 2015-16 Fact Sheet Q3 FY 2015-16 Fact Sheet Q4 FY 2015-16
  Transcript of the Call Transcript of Q1 FY16 Transcript of Q2 FY16 Transcript of Q3 FY16 Transcript of Q3 FY16
  Advertisement
  Results - -
  Investor Presentation Investor Presentation Investor Presentation Investor Presentation


Financial Highlights

In Rs. Crore 
  FY 15-16 Q1 H1 9M FY
  Revenue 857 1718 2570
  EBITDA 236 458 667
  Net Profit 126 432 535
  R&D Expenses in P&L 50 107 175
  Total R&D Spends 93 183 275
  EBITDA Margins 28% 27% 26%  
  Net Profit Margins 15% 25% 21%  
 
     
  FY15-16  FY14-15  FY13-14  FY12-13  FY11-12  FY10-11  FY09-10  FY08-09  FY07-08  FY06-07  FY05-06  FY04-05 

 
Quarterly Results
 
 
 
 
 
     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2016, Biocon. All Rights Reserved